208 related articles for article (PubMed ID: 37403798)
1. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
4. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
5. Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice.
Kang WH; Ryu HJ; Kwak S; Yun HY
Front Pharmacol; 2021; 12():793349. PubMed ID: 35058777
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
7. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
8. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
9.
Zhou S; Zhang S; Zheng K; Li Z; Hu E; Mu Y; Mai J; Zhao A; Zhao Z; Li F
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302417
[TBL] [Abstract][Full Text] [Related]
10. Synergy between
Zhu YC; Elsheikha HM; Wang JH; Fang S; He JJ; Zhu XQ; Chen J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725213
[TBL] [Abstract][Full Text] [Related]
11. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
13. IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model.
Feng Y; Yan S; Lam SK; Ko FCF; Chen C; Khan M; Ho JC
Lung Cancer; 2022 Dec; 174():14-26. PubMed ID: 36272280
[TBL] [Abstract][Full Text] [Related]
14. Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.
Battaglia NG; Murphy JD; Uccello TP; Hughson A; Gavras NW; Caldon JJ; Gerber SA; Lord EM
J Immunol; 2022 Aug; 209(3):629-640. PubMed ID: 35840162
[TBL] [Abstract][Full Text] [Related]
15. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
16. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
17. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
[TBL] [Abstract][Full Text] [Related]
18. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8
Hirose S; Mashima T; Yuan X; Yamashita M; Kitano S; Torii S; Migita T; Seimiya H
Cancer Sci; 2024 Mar; 115(3):791-803. PubMed ID: 38258342
[TBL] [Abstract][Full Text] [Related]
20. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]